Difference between revisions of "Atezolizumab (Tecentriq)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.<ref>Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. [http://meetinglibrary.asco.org/content/128983-144 link to abstract]</ref><ref>[http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer] Roche.com, 8/17/2015.</ref> | + | Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.<ref>Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. [http://meetinglibrary.asco.org/content/128983-144 link to abstract]</ref><ref>[http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer] Roche.com, 8/17/2015.</ref><ref name="insert">[http://www.gene.com/download/pdf/tecentriq_prescribing.pdf Atezolizumab (Tecentriq) package insert]</ref><ref>[[Media:Atezolizumab.pdf | Atezolizumab (Tecentriq) package insert (locally hosted backup)]]</ref><ref>[https://www.tecentriq.com/ Tecentriq manufacturer's website]</ref> |
| + | <br>Route: IV | ||
| + | <br>Extravasation: no information | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/zytiga-abiraterone-999651 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[http://www.gene.com/download/pdf/tecentriq_prescribing.pdf Atezolizumab (Tecentriq) package insert]<ref name="insert"></ref> | ||
| + | *[http://www.uptodate.com/contents/atezolizumab-patient-drug-information Atezolizumab (Tecentriq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/atezolizumab-patient-drug-information Atezolizumab (Tecentriq) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 5/18/2016: Granted FDA accelerated approval for the treatment of patients with locally advanced or metastatic [[bladder cancer|urothelial carcinoma]] who | + | *5/18/2016: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm Granted FDA accelerated approval] "for the treatment of patients with locally advanced or metastatic [[bladder cancer|urothelial carcinoma]] who: |
| + | *Have disease progression during or following [[:Category:Platinum_agents|platinum-containing]] chemotherapy | ||
| + | *Have disease progression within 12 months of neoadjuvant or adjuvant treatment with [[:Category:Platinum_agents|platinum-containing]] chemotherapy." | ||
==Also known as== | ==Also known as== | ||
Revision as of 15:11, 10 July 2016
General information
Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[3]
Diseases for which it is used
Patient drug information
- Atezolizumab (Tecentriq) package insert[3]
- Atezolizumab (Tecentriq) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 5/18/2016: Granted FDA accelerated approval "for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy."
Also known as
MPDL3280A, RG7446
References
- ↑ Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. link to abstract
- ↑ Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer Roche.com, 8/17/2015.
- ↑ 3.0 3.1 3.2 Atezolizumab (Tecentriq) package insert
- ↑ Atezolizumab (Tecentriq) package insert (locally hosted backup)
- ↑ Tecentriq manufacturer's website
- ↑ Atezolizumab (Tecentriq) patient drug information (UpToDate)